Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the tropic trial

Annals of Oncology

Volumn 24, Issue 9, 2013, Pages 2402-2408

  Bahl, A ^a   Oudard, S ^b   Tombal, B ^c   Ozguroglu M ^d   Hansen, S ^e   Kocak, I ^f   Gravis, G ^g   Devin, J ^h   Shen, L ^h   De Bono, J S ⁱ   Sartor, A O ^j  

^a BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d ISTANBUL UNIVERSITY   (Turkey)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^g INSTITUT PAOLI CALMETTES   (France)

^h SANOFI   (France)

ⁱ INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^j TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Cabazitaxel; Palliative care; Prostate cancer; Quality of life; Symptom relief; Treatment response

Indexed keywords

CABAZITAXEL; MITOXANTRONE; PREDNISOLONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANALGESIC ACTIVITY; ARTICLE; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL EVALUATION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG RESPONSE; FOLLOW UP; FUNCTIONAL STATUS; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN ASSESSMENT; PAIN PARAMETERS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY;

CABAZITAXEL; PALLIATIVE CARE; PROSTATE CANCER; QUALITY OF LIFE; SYMPTOM RELIEF; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANALGESICS; ANTINEOPLASTIC AGENTS; HUMANS; MALE; MIDDLE AGED; MITOXANTRONE; NEOPLASM METASTASIS; PAIN; PAIN MEASUREMENT; PALLIATIVE CARE; PERIPHERAL NERVOUS SYSTEM DISEASES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; QUALITY OF LIFE; SURVIVAL; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 84883402878     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt194     Document Type: Article

References (23)

1. Malik Z, di Lorenzo G, Basaran M et al. Cabazitaxel (Cbz) + prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D): interim results from compassionate-use programme (CUP) and early-access programme (EAP). In European Society of Medical Oncology Congress, Vienna, Austria, 28 September-2 October, 2012. Poster 931P.
2. ® (cabazitaxel) Injection, Summary of Product Characteristics. Paris, France, 2013; http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002018/human_med_001428.jsp&mid=WC0b01ac058001d124 (4 April 2013, date last accessed).(4 April 2013, date last accessed)
3. ® (cabazitaxel) Injection, Prescribing Information. Bridgewater, NJ, USA, 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201023lbl.pdf (4 April 2013, date last accessed).
4. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-1154.
5. Oudard S. TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. Future Oncol 2011; 7: 497-506.
6. Colloca G, Colloca P. Health-related quality of life assessment in prospective trials of systemic cytotoxic chemotherapy for metastatic castration resistant prostate cancer: which instrument we need?. Med Oncol 2011; 28: 519-527.
7. Deshields T, Potter P, Olsen S, et al. Documenting the symptom experience of cancer patients. J Support Oncol 2011; 9: 216-223.
8. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006; 24: 1633-1642.
9. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975; 1: 277-299.
10. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756-1764.
11. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
12. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA- 301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13: 983-992.
13. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-1197.
14. Apolone G, Corli O, Caraceni A, et al. Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group. Br J Cancer 2009; 100: 1566-1574.
15. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU Guidelines on Prostate Cancer. 2012. http://www.uroweb.org/gls/pdf/08%20Prostate%20Cancer_LR%20March%2013th%202012.pdf (4 April 2013, date last accessed).
16. KantoffPW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999; 17: 2506-2513.
17. ®) Prostate Cancer (Version 2.2013). http://www.nccn. org/professionals/physician_gls/pdf/prostate.pdf (4 April 2013, date last accessed).
18. Logothetis CJ, Basch E, Molina A, et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletalrelated events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 2012; 13: 1210-1217.
19. Sternberg CN, Molina A, North S, et al. Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Ann Oncol 2013; 24: 1017-1025.
20. Parker C, Nilsson S, Heinrich D, et al. Updated analysis of the phase III, doubleblind, randomized, multinational study of radium-223 chloride in castrationresistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). J Clin Oncol 2012; 30 (Suppl): LBA4512.
21. Gater A, Abetz-Webb L, Battersby C, et al. Pain in castration-resistant prostate cancer with bone metastases: a qualitative study. Health Qual Life Outcomes 2011; 9: 88.
22. ® (docetaxel) Injection Concentrate, Intravenous Infusion (IV) Prescribing Information. NJ, USA: Bridgewater, 2010. http://www. accessdata.fda.gov/drugsatfda_docs/label/2010/020449s059lbl.pdf (4 April 2013, date last accessed).
23. Armstrong AJ, Garrett-Mayer E, de Wit R, et al. Prediction of survival following firstline chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 2010; 16: 203-211.